Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Don’t Blindly Follow Robinhood Traders into Energy Transfer Stock

By Josh Enomoto, InvestorPlace Contributor

ET stock is one of the most popular Robinhood stocks and it’s easy to see why, thanks to a 20% dividend yield. However, speculators will want to think carefully before diving in.

2 Pros, 2 Cons to Consider Before Deciding on DiamondPeak Stock

By Josh Enomoto, InvestorPlace Contributor

With so many EV plays out, you may be tempted to dismiss DiamondPeak stock. However, here are the pros and cons to consider before you make your ultimate decision.

Investors Should Be Realistic with Tilray Stock

By Josh Enomoto, InvestorPlace Contributor

On paper, Tilray stock is supported by attributes that make it attractive during a pandemic. But the details tell a different story.

Understand the Science Before Deciding on Sorrento Therapeutics

By Josh Enomoto, InvestorPlace Contributor

SRNE stock was one of the top performers of this year. But just as quickly, shares have faded, and I'm not sure its Covid-19 pipeline will pan out.

Why Science and Economics Might Justify CureVac

By Josh Enomoto, InvestorPlace Contributor

Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?

Load More